Pursuant to the authorization granted by the annual general meeting on 5 May 2021, the board of directors of Ascelia Pharma AB (”Ascelia”) has resolved to issue and immediately thereafter repurchase 294,729 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2021, which was adopted by the annual general meeting on 5 May 2021.
Pursuant to the authorization granted by the annual general meeting on 5 May 2021, the board of directors of Ascelia has resolved on a directed issue of 294,729 series C shares to Skandinaviska Enskilda Banken AB (“SEB”). The subscription price per share amounts to SEK 1, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 294,729 series C shares from SEB at a price corresponding to the subscription price.
The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of matching shares and performance shares to employees within Ascelia who are participating in the share saving program LTI 2021, which was adopted by the annual general meeting on 5 May 2021, and, in terms of liquidity, to hedge payments of future social security contributions related to LTI 2021. Allotment of matching shares and performance shares in LTI 2021 shall take place within 30 days from the publication of the financial report for the period July – September 2024.
Since previously, Ascelia holds 908,186 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.